Sumitomo Mitsui DS Asset Management Company Ltd Buys 11,580 Shares of Amgen Inc. (NASDAQ:AMGN)

Sumitomo Mitsui DS Asset Management Company Ltd lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 4.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 282,927 shares of the medical research company’s stock after acquiring an additional 11,580 shares during the quarter. Amgen accounts for about 1.0% of Sumitomo Mitsui DS Asset Management Company Ltd’s investment portfolio, making the stock its 20th largest holding. Sumitomo Mitsui DS Asset Management Company Ltd owned 0.05% of Amgen worth $91,162,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in AMGN. Park Avenue Securities LLC lifted its holdings in Amgen by 1.1% during the first quarter. Park Avenue Securities LLC now owns 31,650 shares of the medical research company’s stock valued at $8,999,000 after purchasing an additional 353 shares in the last quarter. Inscription Capital LLC bought a new stake in Amgen during the first quarter valued at about $331,000. LexAurum Advisors LLC lifted its position in shares of Amgen by 23.7% in the first quarter. LexAurum Advisors LLC now owns 1,212 shares of the medical research company’s stock valued at $345,000 after acquiring an additional 232 shares in the last quarter. Tealwood Asset Management Inc. grew its position in shares of Amgen by 1.2% during the first quarter. Tealwood Asset Management Inc. now owns 5,277 shares of the medical research company’s stock worth $1,500,000 after purchasing an additional 64 shares in the last quarter. Finally, First Affirmative Financial Network raised its stake in Amgen by 6.4% during the 1st quarter. First Affirmative Financial Network now owns 1,259 shares of the medical research company’s stock valued at $358,000 after purchasing an additional 76 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Down 0.1 %

Shares of AMGN stock opened at $321.33 on Friday. The stock has a 50 day simple moving average of $326.08 and a 200-day simple moving average of $311.63. Amgen Inc. has a 1-year low of $249.70 and a 1-year high of $346.85. The company has a market cap of $172.37 billion, a price-to-earnings ratio of 45.90, a PEG ratio of 2.86 and a beta of 0.61. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.01 by ($0.04). The firm had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. Amgen had a return on equity of 161.72% and a net margin of 10.12%. The company’s quarterly revenue was up 20.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.00 earnings per share. On average, equities research analysts expect that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were given a $2.25 dividend. The ex-dividend date was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.80%. Amgen’s dividend payout ratio (DPR) is presently 128.57%.

Analyst Ratings Changes

AMGN has been the subject of a number of research analyst reports. Cantor Fitzgerald began coverage on shares of Amgen in a report on Friday, September 27th. They set an “overweight” rating and a $405.00 price objective for the company. Sanford C. Bernstein initiated coverage on shares of Amgen in a research note on Thursday. They issued an “outperform” rating and a $380.00 price objective for the company. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $305.00 price objective (down from $310.00) on shares of Amgen in a research note on Wednesday, August 7th. Oppenheimer restated an “outperform” rating and set a $380.00 price target on shares of Amgen in a report on Wednesday, August 7th. Finally, Bank of America boosted their price objective on shares of Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $329.48.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.